Sugar-Modified Lenalidomide Derivatives for Solubility

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing lenalidomide and pomalidomide derivatives have poor water solubility, making them difficult to formulate into injectable or eye drop preparations, and they also pose teratogenic side effects.

Innovation Solution

Introducing a sugar or sugar derivative to the amino group on the phthalimide moiety of lenalidomide or pomalidomide significantly improves water solubility and reduces teratogenic side effects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If lenalidomide or pomalidomide is used as oral capsule preparation, then therapeutic efficacy is maintained, but water solubility is poor making injectable formulation difficult

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidwater solubility

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent modifies the chemical structure of lenalidomide or pomalidomide by introducing a sugar or sugar derivative moiety at the amino group position, changing the physical-chemical parameters of the compound to improve water solubility while preserving therapeutic activity

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite molecular structure by combining the thalidomide core with sugar or sugar derivative moieties, resulting in a hybrid compound that exhibits both the therapeutic properties of the parent compound and the solubility enhancement from the sugar component

Inventive Principle:

Principle #40Composite materials

2Reliability

If lenalidomide or pomalidomide is administered orally in capsule form, then therapeutic effect is achieved, but teratogenic side effects occur

Engineering Contradiction:

Improvetherapeutic effectVSAvoidteratogenic side effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent modifies the pharmacological properties of lenalidomide or pomalidomide by introducing sugar or sugar derivative moieties, which changes the binding characteristics and reduces teratogenicity while maintaining anti-myeloma activity

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent converts the potentially harmful teratogenic effects into beneficial outcomes by using sugar or sugar derivative modifications that selectively reduce harmful side effects while preserving therapeutic efficacy, thereby improving the safety profile

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Ease of operation

If capsule size is reduced for easier swallowing, then ease of administration is improved, but dissolution performance may be compromised

Engineering Contradiction:

Improveease of administrationVSAvoiddissolution performance

Core Design Contradiction:

Ease of operationVSManufacturing precision

Solution Approach 1:

The patent changes the physical properties of the drug substance by introducing hydrophilic sugar moieties, which improves dissolution characteristics and allows for smaller capsule sizes that still achieve adequate dissolution performance

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20250197438A1Immunoregulatory amide derivative with improved material properties

Publication Date: 2025.06.19 AEVIS BIO INC

AI summary

The present invention relates to a novel thalidomide-based compound derivative having significantly improved water solubility due to the introduction of a sugar or sugar derivative into lenalidomide or pomalidomide, which are thalidomide-based compounds, wherein the lenalidomide or pomalidomide derivative according to the present invention has significantly increased water solubility compared to conventional lenalidomide or pomalidomide and can thus be formulated into an injection or eye drop formulation. Therefore, the lenalidomide or pomalidomide derivative can be administered in the form of a high concentration therapeutic agent to a local area, and can be easily administered in combination with a different therapeutic agent developed as an injection or eye drop formulation.